These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38441236)

  • 1. Prevalence of Kratom Use Disorder Among Kratom Consumers.
    Hill K; Grundmann O; Smith KE; Stanciu CN
    J Addict Med; 2024 May-Jun 01; 18(3):306-312. PubMed ID: 38441236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Kratom Use Disorder and Withdrawal Among an Online Convenience Sample of US Adults.
    Smith KE; Dunn KE; Rogers JM; Garcia-Romeu A; Strickland JC; Epstein DH
    J Addict Med; 2022 Nov-Dec 01; 16(6):666-670. PubMed ID: 35220331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kratom addiction per DSM-5 SUD criteria, and kratom physical dependence: Insights from dosing amount versus frequency.
    Rogers JM; Weiss ST; Epstein DH; Grundmann O; Hill K; Smith KE
    Drug Alcohol Depend; 2024 Jul; 260():111329. PubMed ID: 38788532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ecological Momentary Assessment of Self-Reported Kratom Use, Effects, and Motivations Among US Adults.
    Smith KE; Panlilio LV; Feldman JD; Grundmann O; Dunn KE; McCurdy CR; Garcia-Romeu A; Epstein DH
    JAMA Netw Open; 2024 Jan; 7(1):e2353401. PubMed ID: 38277146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study.
    Schimmel J; Amioka E; Rockhill K; Haynes CM; Black JC; Dart RC; Iwanicki JL
    Addiction; 2021 Jan; 116(1):176-181. PubMed ID: 32285981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic.
    Garcia-Romeu A; Cox DJ; Smith KE; Dunn KE; Griffiths RR
    Drug Alcohol Depend; 2020 Mar; 208():107849. PubMed ID: 32029298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating health information provided to kratom consumers by good manufacturing practice-qualified vendors.
    Hill K; Gibson S; Grundmann O; Smith KE; Ballard J; Stanciu CN
    Subst Abuse Treat Prev Policy; 2023 Apr; 18(1):21. PubMed ID: 37041624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the self-reported motivations of kratom (
    Grundmann O; Veltri CA; Morcos D; Knightes D; Smith KE; Singh D; Corazza O; Cinosi E; Martinotti G; Walsh Z; Swogger MT
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):433-444. PubMed ID: 35389321
    [No Abstract]   [Full Text] [Related]  

  • 9. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users.
    Singh D; Müller CP; Vicknasingam BK
    Drug Alcohol Depend; 2014 Jun; 139():132-7. PubMed ID: 24698080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and characteristics of self-reported kratom use in a representative US general population sample.
    Covvey JR; Vogel SM; Peckham AM; Evoy KE
    J Addict Dis; 2020; 38(4):506-513. PubMed ID: 32657217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of psychotic symptoms in kratom (Mitragyna speciosa Korth.) Users in Malaysia.
    Leong Bin Abdullah MFI; Singh D; Swogger MT; Rahim AA; Vicknasingam B
    Asian J Psychiatr; 2019 Jun; 43():197-201. PubMed ID: 31302592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severity of Kratom (Mitragyna speciosa Korth.) Psychological Withdrawal Symptoms.
    Singh D; Narayanan S; Müller CP; Swogger MT; Rahim AA; Leong Bin Abdullah MFI; Vicknasingam BK
    J Psychoactive Drugs; 2018; 50(5):445-450. PubMed ID: 30152738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severity of Pain and Sleep Problems during Kratom (Mitragyna speciosa Korth.) Cessation among Regular Kratom Users.
    Singh D; Narayanan S; Vicknasingam BK; Prozialeck WC; Ramanathan S; Zainal H; Harun SN
    J Psychoactive Drugs; 2018; 50(3):266-274. PubMed ID: 29558272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Kratom use and health impact in the US-Results from an online survey.
    Grundmann O
    Drug Alcohol Depend; 2017 Jul; 176():63-70. PubMed ID: 28521200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, Characteristics, and Reasons for Kratom Use among Psychiatrically Ill Inpatients Who Use Substances.
    Stanciu CN; Ahmed S; Sarfraz Z; Nimavat N; Healey CJ; Grundmann O; Ballard JR; Henningfield J
    J Dual Diagn; 2024; 20(2):87-97. PubMed ID: 38153407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kratom use and mental health: A systematic review.
    Swogger MT; Walsh Z
    Drug Alcohol Depend; 2018 Feb; 183():134-140. PubMed ID: 29248691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-reported Health Diagnoses and Demographic Correlates With Kratom Use: Results From an Online Survey.
    Bath R; Bucholz T; Buros AF; Singh D; Smith KE; Veltri CA; Grundmann O
    J Addict Med; 2020; 14(3):244-252. PubMed ID: 31567595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users.
    Smith KE; Bunting AM; Walker R; Hall MT; Grundmann O; Castillo O
    J Psychoactive Drugs; 2019; 51(4):311-322. PubMed ID: 30961450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for Management of 'Kratom Use Disorder': A Systematic Literature Review With Survey of Experts.
    Stanciu C; Ahmed S; Hybki B; Penders T; Galbis-Reig D
    WMJ; 2021 Apr; 120(1):54-61. PubMed ID: 33974767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Health Impact of Long-Term Kratom (
    Saingam D; Singh D; Geater AF; Assanangkornchai S; Jitpiboon W; Latkin C
    Subst Use Misuse; 2023; 58(10):1212-1225. PubMed ID: 37270449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.